• Users Online: 365
  • Print this page
  • Email this page
 
ORIGINAL ARTICLE
Ahead of Print

A study on safety and clinical efficacy of COVID-19 vaccines among adults in South India: A cross-sectional study


1 Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bangalore, Karnataka, India
2 Department of Medical Intern, Kempegowda Institute of Medical Sciences, Bangalore, Karnataka, India
3 Scientist D (Medical), ICMR-National Centre for Disease Informatics and Research, Bangalore, Karnataka, India
4 Department of Community Medicine, Akash Institute of Medical Sciences and Research Centre, Bangalore, Karnataka, India

Correspondence Address:
Hulugappa Lakshmi,
Department of Community Medicine, Akash Institute of Medical Sciences and Research Centre, Bengaluru, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/am.am_92_22

Introduction: COVID-19 virus caused a pandemic in 2020. Since vaccine was the only modality to combat the pandemic, the development of vaccine was fast tracked and made available within 1 year of detecting the virus. Objective: The objective of this study was to assess the safety and clinical efficacy of the COVID-19 vaccines. Materials and Methods: This was a cross-sectional study conducted between June 2021 and September 2021 in Bengaluru using digital data capture. Data pertaining to sociodemographic profile, details of the vaccine administered, adverse events developing within 7 days of vaccine administration, and breakthrough infection were collected. Descriptive statistics such as frequencies, percentages, and mean and standard deviation were used. Inferential statistics such as the Chi-square test were used to test association. Results: The study involved 103 study participants. Totally 100 (97.08) participants had taken Covishield and 3 (2.92) had taken Covaxin. Only 3 (2.9%) study participants had breakthrough infections and all these three participants had taken Covishield. Ninety-four (91.26%) of study participants had taken at least one dose of COVID-19 vaccine. A total of 62 (60.19%) participants had one or the other adverse reaction following vaccination. Only 3 (2.9%) study participants had breakthrough infections and all these three participants had taken Covishield. Conclusion: The given COVID-19 vaccines are safe and clinically efficacious with no statistically significant difference between the COVID-19 vaccine type and adverse reaction or with the incidence of breakthrough infection.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Anwith HS
    -  Mariyam D
    -  Madhusudan M
    -  Chethana R
    -  Lakshmi H
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed206    
    PDF Downloaded11    

Recommend this journal